Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 12:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria

-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU)-- BTK inhibition through the SH2 domain results in...
February 10, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D.,...
January 10, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D.,...
November 25, 2024 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Participate in Two Investor Conferences in December

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease, today announced that members of Recludix’s...
November 14, 2024 10:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis

-REX-7117 is an oral, potent and selective STAT3 SH2 domain inhibitor, which demonstrated strong efficacy in an in vivo model of inflammatory arthritis -STAT3 inhibition does not impair the...
August 05, 2024 06:05 ET | Source: Recludix Pharma, Inc.

Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease and cancer, today announced that Fierce Biotech has...
May 17, 2024 15:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting

-- In a preclinical model of psoriasis, the efficacy of oral small molecule REX-7117 was comparable to an anti-IL-17A biologic SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader...
April 23, 2024 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray

Newly appointed head of R&D, Dr. Nirula, joins Recludix from Eli Lilly with over two decades of clinical development experience SAB member, Dr. Ray, has over two decades of experience in...
February 28, 2024 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Participate in Two Investor Conferences in March

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
February 06, 2024 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at Two Investor Conferences in February

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...